Dec 28 (Reuters) - IMV Inc IMV.TO :
* IMV REPORTS UPDATE ON COVID-19 VACCINE PROGRAM
* IMV INC - VACCINE CANDIDATE IS STABLE AT 2°C TO 8°C AND ROOM TEMPERATURE FOR AT LEAST 3 MONTHS AND ONGOING
* IMV INC - PRECLINICAL STUDIES AND REVISED CLINICAL PLAN TO ACCOUNT FOR EVOLVING REGULATORY LANDSCAPE AND EMERGENCE OF NEW VARIANTS
* IMV - PRECLINICAL SAFETY, LONG DURATION OF ANTIBODY TITERS & POTENTIAL FOR PROTECTION DEMONSTRATED IN PRECLINICAL IMMUNOGENICITY, CHALLENGE STUDIES
* IMV - CO PLANNING TO CONDUCT COMPLEMENTARY PRECLINICAL STUDIES INCLUDING TESTING ON NEW VARIANTS & WILL PROVIDE AN UPDATE IN Q1 2021